Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HCN1 | O60741 | 1/20 | 0.40 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437597 | 0.86 | CYP2D6 (0.50) | CYP2D6P2RX7MC4RLMNAMEN1 | |
| SCHEMBL12513648 | 0.84 | MEN1 (0.52) | CYP2D6P2RX7MEN1KMT2A | |
| SCHEMBL12437486 | 0.82 | HCN1 (0.60) | CYP2D6P2RX7TDP1LMNAHCN1 | |
| SCHEMBL12437555 | 0.82 | P2RX7 (0.53) | CYP2D6P2RX7LMNA | |
| SCHEMBL12437383 | 0.79 | MEN1 (0.49) | LMNAMEN1KMT2A | |
| SCHEMBL12437381 | 0.78 | HRH3 (0.48) | LMNAMEN1KMT2A | |
| SCHEMBL12437413 | 0.78 | HRH3 (0.48) | LMNAMEN1KMT2A | |
| SCHEMBL12437494 | 0.78 | ATM (0.50) | P2RX7LMNAMEN1KMT2ATP53 | |
| SCHEMBL12437567 | 0.77 | TP53 (0.52) | CYP2D6TDP1LMNAMEN1KMT2A | |
| SCHEMBL12437569 | 0.76 | KAT6A (0.44) | CYP2D6P2RX7MC4RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | CYP2D6 1488/4885P2RX7 4097/4885TDP1 371/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | CYP2D6 1488/4885P2RX7 4097/4885TDP1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.